Abstract
The pharmacokinetic characteristics of brivaracetam are described and the interaction effects of concomitant antiseizure medications on brivaracetam in terms of its pharmacokinetics and pharmacodynamics are highlighted.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Klotz KA, Hirsch M, Heers M, Schulze-Bonhage A, Jacobs J. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia. 2019;60:e74–7.
Hagemann A, Klimpel D, Bien CG, Brandt C, May TW. Influence of dose and antiepileptic comedication on brivaracetam serum concentrations. Epilepsia. 2020;61:e43–8.
Summary of product characteristics: Brivaracetam (Briviact). UCB Pharma Ltd. Last update 27 Nov 2020.
Biton V, Berkovic SF, Abou-Khalil B, Sperling MR, Johnson ME, Lu S. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia. 2014;55:57–66.
Moseley BD, Chanteux H, Nicolas JM, Laloyaux C, Gidal B. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020;163:106327.
Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol. 2017;73:727–33.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Patsalos, P.N. (2022). Brivaracetam. In: Antiseizure Medication Interactions. Springer, Cham. https://doi.org/10.1007/978-3-030-82790-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-030-82790-8_3
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-82789-2
Online ISBN: 978-3-030-82790-8
eBook Packages: MedicineMedicine (R0)